Phase Ib Study Of The Novel Anti-Cxcr4 Antibody Ulocuplumab (Bms-936564) In Combination With Lenalidomide Plus Low-Dose Dexamethasone, Or With Bortezomib Plus Dexamethasone In Subjects With Relapsed Or Refractory Multiple Myeloma

Background: CXCR4 is a chemokine receptor over-expressed on > 75% of cancers, including malignant plasma cells. Ulocuplumab (BMS- 936564) is a first in class, fully human IgG4 monoclonal anti-CXCR4 antibody which inhibits the binding of CXCR4 to CXCL12. Ulocuplumab induces apoptosis of CXCR4+ multiple myeloma cell lines and has single agent activity in vivo in MM tumor xenograft models. It is thus hypothesized that Ulocuplumab may improve the overall response rate to standard therapy in relapsed-refractory multiple myeloma (rel/ref MM) by distinct mechanisms of action, i.e., mobilization and apoptosis of malignant plasma cells and immune regulation.